Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $234K, compared with -$547K a year earlier. Trailing-twelve-month EBITDA was -$6.67M.
Context
- EBITDA amounted to 16.7% of revenue in FY2025, up 6.6 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $14.66M (+296.7%) for the fiscal year ending Dec 2026, a step up from the -255.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $234K+105.4% QoQ
- Last fiscal yearDec 2025
- -$7.45M-255.3% YoY
- LTMMar 2026
- -$6.67M+35.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +142.8% | +139.2% | -3.6 pp |
| 1 year | -255.3% | +296.7% | +552.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (7.45M) USD
- Year-over-year change
- -255.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.45M) | -255.3% |
| FY2024 | 2024-12-31 | 4.8M | +138.8% |
| FY2023 | 2023-12-31 | (12.36M) | +45.3% |
| FY2022 | 2022-12-31 | (22.59M) | -31.2% |
| FY2021 | 2021-12-31 | (17.22M) | — |
EBITDA vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's LTM Mar 2026 EBITDA of -$6.67M is the highest of the 11 companies compared; the peer median is -$61.27M.
- Its year-over-year change of +35.5% is the 3rd highest of 11, against a peer median of -32.0%.
- EBITDA amounts to 13.1% of revenue for FENC, versus a peer median of 727.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$6.67M | +35.5% | — | 13.1% | |
| LTM Mar 2026 | -$38.09M | -800.9% | — | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$45.49M | -75.7% | — | — |
| LTM Mar 2026 | -$46.56M | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$50.77M | +11.7% | — | — | |
| LTM Mar 2026 | -$52.72M | +20.1% | — | 161.1% | |
| LTM Mar 2026 | -$69.83M | -147.0% | — | — | |
| LTM Mar 2026 | -$76.13M | +39.6% | — | 455.3% | |
| LTM Mar 2026 | -$84.35M | -214.9% | — | 142957.6% | |
| LTM Mar 2026 | -$111.97M | +23.4% | — | 999.5% | |
| LTM Mar 2026 | -$158.55M | -341.7% | — | 8932.3% | |
| Peer median (excluding FENC) | -$61.27M | -32.0% | — | 727.4% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1.54M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | 0 | 86K | 1.26M | 3.18M | 3.76M |
| Gross Profit | 0 | 1.45M | 19.99M | 44.35M | 40.88M |
| Gross Margin | — | 94.4% | 94.1% | 93.3% | 91.6% |
| Research & Development | 4.98M | 3.53M | 56K | 307K | 250K |
| Selling, General & Admin | 12.24M | 20.51M | 32.71M | 41.48M | 46.91M |
| Operating Expenses | 17.22M | 24.19M | 33.05M | 41.88M | 47.22M |
| Depreciation & Amortization | 16K | 149K | 287K | 800K | 103K |
| EBITDA | (17.22M) | (22.59M) | (12.36M) | 4.8M | (7.45M) |
| EBITDA Margin | — | -1471.5% | -58.2% | 10.1% | -16.7% |
| Operating Income | (17.22M) | (22.74M) | (13.06M) | 2.48M | (6.35M) |
| Operating Margin | — | -1481.3% | -61.4% | 5.2% | -14.2% |
| Interest Income | 54K | 195K | 441K | 1.59M | 787K |
| Interest Expense | 126K | 978K | 3.39M | 4.07M | 2.08M |
| Other Income / Expenses | (123K) | (976K) | (2.99M) | (2.55M) | (3.29M) |
| Income Before Tax | (17.35M) | (23.71M) | (16.05M) | (71K) | (9.64M) |
| Pre-Tax Margin | — | -1544.9% | -75.5% | -0.1% | -21.6% |
| Income Tax Expense | 0 | 0 | 0 | 365K | 106K |
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Net Margin | — | -1544.9% | -75.5% | -0.9% | -21.8% |
| EPS (Basic) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| EPS (Diluted) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| Weighted Avg Shares | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
| Weighted Avg Shares (Diluted) | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.